Searching for early-detection genetic markers and treatment options for 20 to 39 year olds.
Melanoma is the most prevalent cancer in 20-39 year olds. Traditional treatments can cause long term damage to growing bodies.
Postdoctoral Fellow, Dr James Wilmott is hoping to help by searching for early-detection genetic markers and treatment options that are specific to this age group.
“New drugs that target genetic mutations specific to a patient’s melanoma look extremely promising. But young patients have been largely overlooked in this kind of research. This study will address that gap by characterising all the gene mutations in blood and melanomas from young people with melanoma.”